Alternative Investments - Gold, REITs, Crypto, Commodities, etc.

Tag: value investing

Innovative Industrial Properties IIPR investment illustration featuring cannabis real estate, biotech facilities, a $1M insider buy and 14.7% yield.

🌿 Innovative Industrial Properties ($IIPR): $1M Insider Buy, 14.7% Yield & the Biotech Pivot 🌿🧪

Innovative Industrial Properties ($IIPR) is stirring up an extraordinary investment debate. Its executive chairman just invested $1 million in preferred shares, the common stock offers an indicated dividend yield near 14.7%, institutional ownership approaches 80%, and short interest exceeds 15%. Meanwhile, a $270 million life sciences investment could reshape this battered cannabis REIT. Is IIPR an overlooked income-and-recovery opportunity—or a dividend trap? We examine the evidence through the FunStock Method™. FunStock Index™: 7.65/10. 🌿🧪

Read entire article

Tags: AFFO, Alan Gold, Biotechnology, BlackRock, buy or sell IIPR, Cannabis REIT, Cannabis Stocks, CannabisREIT, Deep Value Stocks, Dividend Sustainability, Dividend Trap, featured-diversify, featured-insiders, featured-value, FUNanc1al, FunStock Index, FunStock Method, FunStockIndex, High Dividend Stocks, HighYield, hub-diversify, hub-insiders, hub-value, IIPR, IIPR Dividend, IIPR Dividend Yield, IIPR Preferred Stock, IIPR Stock, Income Investing, Innovative Industrial Properties, InnovativeIndustrialProperties, Insider Buying, Insider Trading, InsiderBuying, Institutional Ownership, IQHQ, Life Sciences Real Estate, Real Estate Investing, REIT Investing, REITs, risks buying IIPR, Short Interest, Short Squeeze, Value Investing, why buy IIPR
KBDC stock analysis showing a 12.3% yield, $5.2M Jim Robo insider buy and deep NAV discount against rising private-credit risks.

🏦 Kayne Anderson BDC (KBDC): A $5.2M Insider Buy, 12.3% Yield—and the BDC Trap 💰⚡

Kayne Anderson BDC Chairman Jim Robo just put $5.2 million behind KBDC near $13. Add a 12.3% yield, deep discount to NAV and covered dividend, and the stock looks irresistible—until you examine NAV erosion, leverage and private-credit risk.

 

Read entire article

Tags: BDC, business development companies, buy or sell KBDC, CarpeDiem, credit risk, dividend stocks, dividend yield, DividendInvesting, featured-diversify, featured-insiders, FUNanc1al, FunStock Index, FunStock Method, high yield stocks, HighYield, hub-diversify, hub-insiders, income investing, insider buying, insider purchases, Jim Robo, JimRobo, Kayne Anderson BDC, Kayne Anderson BDC stock, KayneAnderson, KBDC, KBDC stock, NAV, NAV discount, net asset value, net investment income, NII, private credit, PrivateCredit, risks buying KBDC, value investing, ValueInvesting, why buy KBDC
Illustration of a coal mine with a confident investor studying charts while bullish insider buying collides with bearish market forces, highlighting Alpha Metallurgical Resources (AMR) stock analysis and commodity investing risk.

Alpha Metallurgical Resources (AMR) Stock Analysis: Should You Follow a $26 Million Insider Buying Spree?

Alpha Metallurgical Resources (NYSE: AMR) looks compelling on paper: legendary insider buying, aggressive buybacks and a pristine balance sheet. But commodity cycles, recent losses and long-term industry headwinds suggest caution may still be the wiser investment.

Read entire article

Tags: Alpha Metallurgical Resources, AlphaMetallurgical, AMR, AMR stock, BlackRock, buy or sell AMR, coal stocks, CoalStocks, Commodities, commodity investing, CyclicalIndustry, FUNanc1al, insider buying, InsiderBuying, Kenneth Courtis, KennethCourtis, metallurgical coal, mining stocks, Renaissance Technologies, risks buying AMR, short squeeze, ShortSqueeze, steel industry, stock analysis, value investing, ValueInvesting, Wall Street, why buy AMR
Illustration of a futuristic life science research campus under reconstruction, with cranes and glowing laboratory buildings, symbolizing Alexandria Real Estate’s turnaround in biotech real estate.

Alexandria Real Estate (ARE): The Life Science “Dr. Frankenstein” Pivot — Rebuilding the Lab from the Floor Up

Alexandria Real Estate (ARE) is the king of life science labs—and one of the most punished REITs of the last five years. After a brutal dividend cut, asset write-downs, and a 75% drawdown, the founder just bought $1.3M of stock and the company is buying back shares. Is this a broken experiment—or a classic cycle-bottom setup?

 

Read entire article

Tags: Alexandria Real Estate, ARE, Biotech, Biotech Real Estate, BiotechInvesting, BiotechTurnarounds, buy or sell ARE, Dividend Stocks, featured-diversify, featured-insiders, FUNanc1al, FUNanc1al Edge, Healthcare Real Estate, hub-diversify, hub-insiders, Income Investing, Insider Buying, Lab Space, Life Science REIT, Real Estate Investing, REIT, risks buying ARE, Stock Analysis, Turnaround Stocks, Value Investing, why buy ARE
Cartoon-style digital illustration of a Bunge-branded tractor harvesting moneybags from a golden cornfield labeled “Dividends,” while institutional investors in suits chase behind with pitchforks and a banner reading “Merger, Anyone?”

Bunge: Time for the Big Binge?

🛢️ Agribusiness giant Bunge is getting squeezed—but don’t count it out yet. With a massive merger on deck, insider and institutional support strong, and shares trading at low multiples, could it be time for a contrarian feast?

Read entire article

Tags: Agribusiness Stocks, BG stock, Bunge Global, Bunge Viterra Merger, Commodities and Agriculture, Contrarian Picks, dividend stocks, Food Commodities, Funanc1al Contrarian Picks, Funanc1al Contrarian Plays, Funanc1al Edge, Funanc1al for Investors, Funanc1al Investing, Funanc1alEdge, Funanc1alInvesting, Funanc1alStocks, Glencore Viterra Merger, Institutional Ownership, Shareholder Returns, Stock Market Humor, Value Investing